Capsule

Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia

Retrieved on: 
Friday, April 5, 2024

TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that, in another Australian first, its joint venture, Cortexa Pty.

Key Points: 
  • TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that, in another Australian first, its joint venture, Cortexa Pty.
  • Ltd. (“Cortexa”), is proud to have commenced batch manufacturing of GMP LaNeo® MDMA 40mg capsules to support both clinical trials and clinical use under the TGA’s Authorised Prescriber pathway.
  • In doing so, Cortexa achieves another significant milestone, domestic Australian manufacturing, further strengthening its position as a leader in the Australian psychedelic landscape by executing on its plan to develop a reliable local supply.
  • After a comprehensive due diligence process, Cortexa is pleased to announce it has entered an exclusive arrangement with Perth-based contract manufacturer Optima Ovest (Optima).

Rubicon Organics Reports 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024

2023 and Subsequent Sales & Operational Highlights:

Key Points: 
  • 2023 and Subsequent Sales & Operational Highlights:
    Rubicon Organics has established high-quality partnerships for contract grow and co-manufacturing to complement our own premium production and to satisfy the increasing demand for our brands.
  • Simply Bare™ Organic launched infused pre-rolls under the Simply Bare™ Organic brand, including the “Layer J” in BC and Ontario in October 2023.
  • The Company appointed Margaret Brodie as permanent Chief Executive Officer and Janis Risbin as Chief Financial Officer.
  • Q4 2023 Financial and Market Share Highlights:
    For the three months ended December 31, 2023
    The Company will be hosting a conference call to discuss Q4 2023 results on Thursday, March 28, 2024.

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Retrieved on: 
Tuesday, March 26, 2024

Once issued, this patent is expected to expire no earlier than October 2039.

Key Points: 
  • Once issued, this patent is expected to expire no earlier than October 2039.
  • The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.
  • The allowed claims specifically cover both primary progressive multiple sclerosis and secondary progressive multiple sclerosis.
  • Previously, we reported positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 in progressive multiple sclerosis.

AustinPx Invests in Pharmaceutics and Manufacturing Capabilities to Accelerate Drug Development

Retrieved on: 
Monday, April 8, 2024

The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.

Key Points: 
  • The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
  • The technology enables rapid transition into first-in-human clinical trial material manufacturing, while also reducing the cost of drug product development.
  • “These tools enable scientists and engineers to rapidly develop life-changing therapies with enhanced data and quality.”
    The expanded capabilities are now available for use.
  • The additional capabilities mark another milestone in the growth of AustinPx’s formulation development and manufacturing offerings, as the Company continues to position itself as a leading CDMO in the pharmaceutical industry.

Milan Salone Del Mobile 2024: illycaffè to feature at the design industry's most important international event

Retrieved on: 
Monday, April 8, 2024

MILAN, April 8, 2024 /PRNewswire/ -- illycaffè is getting ready for its star turn at the Milan Design Week.

Key Points: 
  • MILAN, April 8, 2024 /PRNewswire/ -- illycaffè is getting ready for its star turn at the Milan Design Week.
  • Those attending will find the global leader in high-quality sustainable coffee both at the Milan Furniture Fair and around the city at key events that celebrate the collision of beauty, innovation, and sustainability.
  • This theme is perfectly in line with the chosen theme for the 62nd edition of the fair: "Materia Natura".
  • Indeed, the press office will feature the chairs and the new A.I.

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Retrieved on: 
Monday, March 18, 2024

The FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024.

Key Points: 
  • The FDA has set a Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024.
  • The Phase 3 clinical trials achieved all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues.
  • DFD-29 demonstrated statistically significant superiority over both the current standard-of-care treatment, Oracea® 40 mg capsules, and placebo for Investigator’s Global Assessment (IGA) treatment success as well as the reduction in the total inflammatory lesion count in both studies.
  • For the secondary endpoint evaluating erythema (redness) associated with rosacea, DFD-29 showed a statistically significant reduction in Clinician’s Erythema Assessment (CEA) compared to placebo in both clinical trials.”

NatureWorks and IMA Announce Turn-Key Compostable Coffee Pod Solution Compatible for North America

Retrieved on: 
Thursday, April 4, 2024

NatureWorks , a leading manufacturer of polylactic acid (PLA) biopolymers made from renewable resources, has optimized a compostable coffee pod solution compatible with Keurig® brewers for the North American market.

Key Points: 
  • NatureWorks , a leading manufacturer of polylactic acid (PLA) biopolymers made from renewable resources, has optimized a compostable coffee pod solution compatible with Keurig® brewers for the North American market.
  • The partnership between NatureWorks and IMA Coffee began in April 2021 with accelerated testing announced in February of 2022.
  • IMA Coffee and NatureWorks presented on this new coffee pods solution at the AMI Single-Serve Capsules conference held from March 19-20 in Boston, MA.
  • View the full release here: https://www.businesswire.com/news/home/20240404501499/en/
    Every IMA Coffee pod filling and sealing machine can handle compostable coffee pods made from Ingeo™ PLA biopolymer.

Global Immune Health Supplements Outlook Report 2024: Market to Reach $34.73 Billion by 2028 with Amway, Bayer, DSM, Glanbia, Herbalife Nutrition, and Nutramax Laboratories Dominating - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 28, 2024

The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach $34.73 billion by 2028, growing at a CAGR of 8.92%

Key Points: 
  • The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach $34.73 billion by 2028, growing at a CAGR of 8.92%
    The global immune health supplements market is witnessing several dynamic changes after the Coronavirus surge worldwide.
  • In the global immune health supplements market, several leading domestic, national, and international vendors are present.
  • North America accounted for the highest global immune health supplements market share, accounting for over 33% in 2022.
  • High Demand for Immune Health Supplements with Zinc, Vitamin C & D, and Curcumins
    In the immune health supplements market, vitamin C, vitamin D, zinc, and curcumins are the most used and suggested ingredients for immune health.

Sexual Health Supplement Market Size, Share & Trends Analysis Report 2024: Natural Ingredients Lead Market Amid Preference for Organic Products - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024

As per King's College London, ED is estimated that by 2025, 322 million men worldwide are expected to be affected by it.

Key Points: 
  • As per King's College London, ED is estimated that by 2025, 322 million men worldwide are expected to be affected by it.
  • Government-supported sexual health programs indeed have a significant impact on the market.
  • These programs help to increase awareness about sexual health issues, promote safe sex practices and encourage people to take proactive steps to maintain their sexual health.
  • For instance, Australia Department of Health has "Healthysexual" program, which raise awareness about sexual health.

Nintendo Celebrates MAR10 Day With Games, Movie News and a Variety of Mario-Themed Activities

Retrieved on: 
Monday, March 11, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240311148081/en/
    Paper Mario: The Thousand-Year Door arrives on the Nintendo Switch family of systems on May 23.
  • The witty and whimsical RPG arrives on the Nintendo Switch system twenty years after its original debut on Nintendo GameCube.
  • * In honor of MAR10 Day, Nintendo is offering twice the fun with the Nintendo Switch Online 14-Day Free Trial Membership (typically 7 days), available now through March 17 on My Nintendo .
  • Watch the Super Mario Bros. Movie and Check Out the Companion Digital Guidebook – What better way to celebrate MAR10 Day than to watch The Super Mario Bros. Movie?